Overview:

 About AMD

Age-related macular degeneration (ARMD) is an acquired retinal degeneration that significantly impairs central vision as a result of a mix of non-neovascular (abnormalities in the drusen and retinal pigment epithelium) and neovascular (development of choroidal neovascular membrane) derangements. Advanced disease may include subretinal fibrosis, sub-RPE hemorrhage, serous fluid, and focal areas of retinal pigment epithelium (RPE) loss. Franciscus Cornelis Donders and Dr. Albrecht Nagel created the theory of macular degeneration in the early 1980s based on their observations of drusen that resulted in degeneration of the choriocapillaris, the RPE, and thinning of the neuroretina with vision loss. The earliest descriptions of AMD date back to around 300 BC. Thus, several treatment modalities like macular photocoagulation and laser photocoagulation were investigated to reduce the disease’s symptoms. Later, the development of anti-VEGF drugs like Pegaptanib, Ranibizumab, etc. completely changed how AMD was treated. These anti-VEGF agents were applied topically or through intravitreal injections, but there were problems with low patient adherence to the treatment regimen and insufficient frequency of delivery. Intraocular implants were developed to address these problems.

Cut to the present, various therapeutic regimens other than anti-VEGF’s are being developed to manage AMD, including cell-based therapies, gene therapy, visual cycle modulators, neuroprotectors, etc. In addition, various drug delivery methods other than implants are being investigated to increase the bioavailability and penetrability of these therapeutic regimens. Microspheres, hydrogels, polymeric nanoparticles, solid lipid nanoparticles, and liposomes are the major components of these methods.

Classification

Early ARMD is characterised by an abundance of tiny (63 microns, “hard”) or intermediate (63 microns but 125 microns, “soft”) drusen. As intermediate drusen are more specific for ARMD; small drusen are regularly observed in people over the age of 50 and may be an epiphenomenon of ageing.

Intermediate ARMD is characterised by extensive drusen of small or intermediate size or by any drusen that is large (>125 microns); the average diameter of the retinal vein at the edge of the optic disc is 124 microns.

Geographic atrophy or the appearance of choroidal neovascular membrane, as well as any associated complications such subretinal or sub-RPE haemorrhage or serous fluid, and subretinal fibrosis, are indicators of advanced ARMD.

Scope of the Report :

• The report covers the descriptive overview of Age-related Macular Degeneration, explaining its historic events, epidemiology and currently available drug delivery method.
• Comprehensive insight has been provided into the Age-related Macular Degeneration drug delivery methods
• Additionally, an all-inclusive account of both the current and emerging drug delivery methods for Age-related Macular Degeneration is provided, along with the new methods that may replace the current ones, which will have an impact on the current drug delivery landscape.
• By comprehending trends influencing and driving drug delivery methods in the market for age-related macular degeneration, the study gives clients a competitive edge when building business strategies.

Geography

Technology covered: Worldwide

Market covered: Specifically, for USA

Time Period

For technology coverage: 2018 till present

For market analysis: 2023 till 2033

Market Assessment/Forecast :

The report provides assessment and forecast about different drug delivery method like implants/hydrogels/nanoparticles/micro particles. Along with this it also provides assumptions, adoption and insights. The Age-related Macular Degeneration market size in different markets is segregated into two part, Dry-AMD, and Wet-AMD. As per our analysis and estimation, in 2023, the market size of implant used as drug delivery method for AMD was approximately USD 3.6 million which is further expected to increase by 2033

Opportunity Analysis

The report provides identification of problems associated with implants/hydrogels/nanoparticles/micro particles and solutions related to them, also the evolution of these methods from time to time as well as current and future technology trends.

Patent Analysis

The report provides identification of patent filing on different drug delivery method like implants/hydrogels/nanoparticles/micro particles in time period of 2018-2023. Our report provides bibliographic (including Top Assignees, Assignee segmentation, Geographical distribution of top assignees, Filling Trends, Litigations, Legal Status) as well as technology (By disease type, By drug delivery approach, By drug class type, By drug formulation type) analysis

Pipeline Development Activities

The report includes comprehensive information on partnerships, acquisitions, and mergers, as well as licencing and patent information for a drug delivery technique for age-related macular degeneration.

Competitive Intelligence Analysis :

We perform competitively and market Intelligence analysis of the Age-related Macular Degeneration drug delivery method including identification of most likely competitors, emerging competitors, SWOT analysis etc. The inclusion of the analysis entirely depends upon the data availability.

Clinical Trials :

The report provides insights into different therapeutic candidates in phase I, phase II, and phase III stages also analyse key players involved in developing drug delivery methods.

Product Insights :

The report provides insights about different products for these drug delivery method through company segmentation, type of drug delivery method as well as their pipeline.

Age-related Macular Degeneration: Drug Delivery Methods Report Insights

• Age-related Macular Degeneration Product and Patent Insights
• Age-related Macular Degeneration Drug Delivery Method Opportunity
• Age-related Macular Degeneration Pipeline Analysis
• Size and Trends of the Market for Age-Related Macular Degeneration
• Age-related Macular Degeneration Market Opportunities
• Impact of upcoming drug delivery methods on implants, hydrogels, nanoparticle/micro particle

Age-related Macular Degeneration Report Key Strengths

• 10-Years Forecast
• Top players
• Age-related Macular Degeneration Drug Delivery Segmentation
• Key Competition
• Highly Analysed Age-related Macular Degeneration Market

Age-related Macular Degeneration Report Assessment

• Current AMD Drug Delivery Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis
• Emerging company profiles

Age-related Macular Degeneration Market Report Highlights

• The strong pipeline of treatments and clinical trials that will help the market for age-related macular degeneration grow. Research and development for age-related macular degeneration is being impacted by difficulties that companies and academics are evaluating and looking for opportunities to address. The drug delivery method under development focused on novel approaches to treat/improve the disease condition.
• Major players involved in developing drug delivery method for Age-related Macular Degeneration. The market for treatments for age-related macular degeneration will be considerably impacted by the introduction of new drug delivery methods.
• By identifying the general context of the research and development activities, our in-depth analysis of the pipeline assets at various stages of development (phase III and phase II), various emerging trends, comparative analysis of pipeline products with clinical profiles, key competitors, patent filing, launch date, and product development activities will assist the clients in making decisions regarding their drug delivery portfolio.

Reasons to buy

• By comprehending the trends influencing and driving Age-related Macular Degeneration drug delivery strategies, the report will aid in the development of business strategies.
• To comprehend the Age-related Macular Degeneration market’s future, market competition and to gain a thorough understanding of the major market drivers and obstacles.
• Finding strong emerging competitors in the market that will aid in the development of tactics for edging out rivals.
• Marketing initiatives by locating the Age-related Macular Degeneration market’s finest opportunities.
• Comprehension of how the market for age-related macular degeneration will be competitive in the future.
• Detailed patent examination to look for novelty in drug delivery techniques for age-related macular degeneration

In order to give the most precise estimations and forecasts, Wissen Research uses an extensive and iterative research approach that is focused on reducing deviation. The company blends top-down and bottom-up methodologies for market segmentation and quantitative estimation. In addition, data triangulation, which examines the market from three separate angles, is a recurrent topic present in all of our research studies. Important components of the approach used for all of our studies include the following.:

Preliminary data mining

On a wide scale, unprocessed market data is collected. Continuous data filtering makes sure that only verified and authenticated sources are taken into account. Additionally, data is extracted from a wide range of reports in our repository and from a number of reputable premium databases. We gather information from raw material suppliers, distributors, and purchasers to help with this since understanding the entire value chain is crucial for a thorough understanding of the market.

Surveys, technical symposia, and trade magazines are used to gather information on technical concerns and trends. Technical information focusing on white space and freedom of movement is also obtained from an intellectual property standpoint. Additionally, information on the industry’s drivers, constraints, and pricing patterns is obtained. As a result, a variety of original data are included in the material that is then cross-validated and certified with published sources.

Statistical model

We use simulation models to generate our market projections and estimates. Every study receives a special model that is tailored to it. Data for market dynamics, the technology environment, application development, and pricing patterns are gathered and supplied into the model all at once for analysis. The relative relevance of these factors is investigated, and their impact on the forecast period is assessed, using correlation, regression, and time series analysis. The process of market forecasting combines technological analysis with economic strategies, practical business acumen, and subject expertise.

Econometric models are frequently used for short-term forecasting, but technology market models are typically employed for long-term forecasting. These are based on a confluence of the business environment, regulatory environment, economic projection, and technical landscape. In order to develop global estimates, it is preferable to estimate markets from the bottom up by integrating data from key regional markets. This is required to ensure accuracy and a complete comprehension of the subject. Among the variables taken into account for forecasting are:

• Market drivers and restraints, as well as the current and anticipated effects of each

   scenario for raw materials and supply versus pricing patterns

 Regulations and anticipated developments

• Present capacity and anticipated capacity growth to 2033

We give these criteria weights and use weighted average analysis to assess their market influence in order to calculate the anticipated market growth rate.

Data Collection Matrix

1. Introduction

1.1. Historic Period

1.2. Epidemiology

1.3. Objective of the study

2. Overview of the study

2.1. Market Scope / Definition

2.2. Technology Categorization

2.3. Inclusion & Exclusion

3. Qualitative Analysis of the study

3.1. To Provide Opportunity Analysis / Gap Analysis

3.1.1. Problem Solution

3.1.2.Technology Trends

3.1.3. Technology Evolution

3.2. Patent Bibliographic Analysis

3.2.1. Top Assignees

3.2.1.1 Top Assignee of Implant

3.2.1.2. Top Assignee of Hydrogel

3.2.1.3.Top Assignee of Nanoparticles

3.2.2. Technology Focus of Top Assignees

3.2.3. Geographical Distribution of Patents of Top Assignees

3.2.4. Top Countries of Origin

3.2.5. New Entrants

3.2.6. Assignee Segmentation

3.2.7. Legal Status

3.2.8. Key Patents

3.2.8.1. Most Cited Patents

3.2.8.2. Largest Invention Families

3.2.8.3. Most Claim-Heavy Patents

3.2.8.4. Highest Market-Valued Patents

3.2.9. Patents Filing Trends

3.2.9.1. By Disease Type

3.2.9.2. By Drug Delivery Approach

3.2.10. Technology Trends

3.2.10.1. Delivery Approach

3.2.10.1.1. By Disease Type

3.2.10.1.2. By Drugs Delivered

3.2.10.1.3. By Drug Form

3.2.10.2.  Key Insights

3.2.10.2.1. Implant

3.2.10.2.2. Hydrogel

3.2.10.2.3. Nanoparticles

3.3. Scientific Literature Analysis

3.3.1. Literature Filing Trend

3.3.2. Geographic Analysis

3.3.3. Key Summary

3.4. Product Analysis

3.4.1. Graphical Representation

3.4.1.1. Product Type (Segmented by Implants, Hydrogels, Nanoparticles/Micro particles)

3.4.1.2. Product Pipeline Analysis

3.4.2. Portfolio for Approved Products

3.5. Clinical Trials

3.5.1. Clinical Trial Filing Timeline

3.5.2. Clinical Trial Status Versus Companies / Sponsors

3.5.3. Clinical Trial Phases with Respect to Specific Drug Delivery Approach

3.5.4. Illustration of Different Clinical Trial Phases

3.5.5. Key Insights

4. Competitive Analysis

4.1. Identification of Most Likely Competitors

4.2. Identification of Emerging Competitors in This Area

4.3. SWOT Analysis of Top Players

5. Market Dynamics

5.1. To provide drivers and restraints

5.2. Company Benchmarking

5.3. Provide top players in the market

5.4. Overview of start-ups

5.5. Strategic Activities

5.6. Distribution channel

6. Quantitative Analysis of the study

6.1. By Drug Delivery Method type

6.1.1. Through Implant / Inserts

6.1.1.1. Market size, By Country (North America)

6.1.1.2. Market share, By Region

6.1.2. Through Hydrogels

6.1.2.1. Market size, By Country (North America)

6.1.2.2. Market share, By Region

6.1.3. Through Nanoparticles / Micro particles

6.1.3.1. Market size, By country (North America)

6.1.3.2. Market share, By Region

6.2. Research Methodology and Assumptions for Market Forecasting

LIST OF FIGURES

LIST OF GRAPHS

LIST OF TABLES